Biocon is currently trading at Rs. 462.00, up by 3.20 points or 0.70% from its previous closing of Rs. 458.80 on the BSE.
The scrip opened at Rs. 459.00 and has touched a high and low of Rs. 466.25 and Rs. 459.00 respectively. So far 25605 shares were traded on the counter.
The BSE group 'A ' stock of face value Rs. 5 has touched a 52 week high of Rs. 553.70 on 04-Jul-2014 and a 52 week low of Rs. 319.00 on 17-Sep-2013.
Last one week high and low of the scrip stood at Rs. 481.05 and Rs. 454.00 respectively. The current market cap of the company is Rs. 9257.00 crore.
The promoters holding in the company stood at 60.97% while Institutions and Non-Institutions held 20.05% and 18.97% respectively.
Biocon, Asia’s premier biotechnology company, has kicked off a series of patient outreach programs to mark a Decade of Excellence in Affordable Insulin Therapy, through which it has been touching the lives of lakhs of diabetic patients. Biocon was an early pioneer in the development of generic recombinant human Insulin (rh-lnsulin) and introduced it to patients in India in 2004.
As a part of the initiative, special programs like health camps for senior citizens are being organized in several cities across India. In Bangalore, over 40 senior citizens underwent a comprehensive free health check-up. The camp held cardio-diabetic screening, health & eye checkups followed by doctor consultations and a session on diabetes awareness.
The company’s engagement with the senior citizens who underwent screening at the health camp will extend to subsidized/free lifetime medication (oral cardio, anti-diabetics & insulins) and distribution of free optical devices.
The health camp was organized as a part of Biocon’s efforts to improve the quality of life of patients, especially the less privileged & neglected members of society who deserve that extra attention and care in the advancing years.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.90 |
| Dr. Reddys Lab | 1221.90 |
| Cipla | 1232.10 |
| Zydus Lifesciences | 926.80 |
| Lupin | 2323.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: